Salah is absolutely up there with Lewandowski: Liverpool boss Klopp    'Then the killing started': Witnesses accuse Tigray fighters    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    Refugees in fear as sentiment turns against them in Turkey    We mustn't lose touch: Muller after Bayern win in Bundesliga    Brazil calls up 8 EPL players for World Cup qualifying    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    France, Germany nominate WHO chief Tedros for a second term    Sisi calls on House, Senate to commence second legislative sessions on 3, 5 October    Africa needs seven-fold rise in COVID-19 vaccine shipments: WHO    Egypt's stocks end the week in green as benchmark EGX 30 adds 0.43%    Huawei Technologies has invested $10 mln over 5 years in innovation centres in Egypt    Egypt to issue its second dollar bonds today    Dubai real-estate firm DAMAC approved to take firm private    Egypt looks forward to resumption of AU-sponsored GERD talks: FM    Egypt electricity minister leads high-level delegation to 65th IAEA General Conference    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    Qa'a play showing at Lycee El Horreya Theatre, Alexandria is a must go    President Sisi says River Nile lifeline for Egyptians, slams Ethiopia's intransigence in GERD talks    UAE-based Alameda to invest around $318 mln in Egypt in five years    Egypt to be removed from England's red travel list on September 22    Jordan hosts energy meeting today to discuss transporting Egyptian gas to Lebanon    Russia permits airlines to resume flights from 49 cities to Egypt    Egypt's Abu Soma Development partners with KOMPASS Education    Sisi: coronavirus vaccines in Africa 'far less' than actual needs    Orange Egypt Introduces Amazon Prime Video    Tokyo Olympics: Cautious opening ceremony, shy start for Egyptians in competitions    Mallawi Museum in Upper Egypt holds recycling workshop for children during Eid Al-Adha    Egypt keen on stable tax policies to attract more investors: Finance Minister    Sudan declares state of emergency as water goes beyond Merowe Dam capacity    Niagara Falls illuminated in Egyptian flag to mark 23 July Revolution anniversary    Capital flows into EM keep recovering after March 2020 slump: Central Bank of Egypt    1 child orphaned every 12 seconds due to COVID-19-associated death: World Bank    Egypt, Japanese Olympic Committee discuss boosting sports cooperation    Ethiopia ready to resume dam talks with no legally binding agreements: Ethiopian official    US emphasises AU's role in mediating Ethiopian damdispute    Sunken city of Thônis-Heracleion in Egypt's Abu Qir bay yields new archaeological treasures    New films, concerts, and destinations for Eid Al-Adha holidays    Egypt, Oman discuss enhancing bilateral economic, investment relations    Al Ahly v Kaizer Chiefs: Cairo giants eye 10th CAF Champions League title    Tunisia hopes to have a UN role in resolving Egypt-Ethiopia dam dispute    Egypt denounces Ethiopia's move to start second filling of giant dam    APO Group enters new exclusive agreement with Getty Images on African press releases and images    On International Museum Day, Egypt opens two new museums at Cairo Airport    Egypt's Ahly is establishing a new stadium, expected to be 'sports complex'    Old Cairo's Al-Fustat will be revamped on Egyptian President's directives    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



BREAKING: Moderna coronavirus vaccine almost 95% effective; early trial shows
Published in Amwal Al Ghad on 16 - 11 - 2020

Moderna Inc announced on Monday its coronavirus vaccine candidate was 94.5 percent effective, becoming the second U.S. company after Pfizer to add growing confidence that vaccines can help end the pandemic.
The news comes a week after Pfizer and BioNTech said their vaccine was more than 90 percent effective.
The results for both Moderna and Pfizer- BioNTech vaccines come from interim analyses of large clinical studies.
In the Moderna study there were 30,000 volunteers, of which half got two doses of the vaccine 28 days apart, and the other half had two shots of a placebo on the same schedule.
The results indicate the vaccine was inducing the kind of immune response that protects people if they were exposed to the coronavirus, the company added.
"This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease," Stéphane Bancel, chief executive officer of Moderna, said in a statement.
Both the Moderna and Pfizer vaccines are using the same technology to make their vaccines. This technology is based on a molecule known as mRNA, or messenger RNA, which contains genetic instructions for making proteins inside cells.
The Moderna and Pfizer- BioNTech studies were conducted using slightly different protocols. To be counted as a coronavirus case, participants in the Moderna study had to have at least two symptoms of disease along with a positive test for the virus.
In the Pfizer- BioNTech study, it is required only one symptom.
Also, Moderna waited 14 days following the second injection to begin counting cases, while Pfizer- BioNTech study started counting at seven days.
Another difference in the two vaccines is that both differ in their storage requirements.
Moderna said its vaccine can be safely stored in freezers at around 25 degrees Fahrenheit (-4 degrees Celsius), a temperature easily reached by a home refrigerator freezer.
Pfizer- BioNTech vaccine required storage in specialised ultracold freezers capable of cooling below -94 degrees Fahrenheit (-70 degrees Celsius).
Moderna also said its vaccine would remain potent for up to 30 days at normal refrigerated temperatures, which should ease distribution.
Pfizer and Moderna are still gathering safety data required by the U.S. Food and Drug Administration (FDA) to get an emergency use authorisation that would allow the companies to distribute the vaccine during the pandemic.
For Moderna vaccine, side effects seen at the interim analysis included pain at the injection site, fatigue, and aching muscles and joints. Its data safety and monitoring board did not identify "any significant safety concerns."
Moderna said it plans to file "in the coming weeks" with the FDA for authorisation of the its vaccine for emergency use.
The drugmaker added that it expects to be able to ship about 20 million vaccine doses in the U.S. by the end of 2020. Next year, it said it expects to be able to make 500 million to 1 billion doses worldwide.


Clic here to read the story from its source.